STOCK TITAN

Co-Diagnostics, Inc. to Present at Upcoming Technology and Health Research Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SALT LAKE CITY, June 15, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting virtually this week at the 28th International Biodetection Technologies Conference as well as hosting a virtual booth at the 65th Annual CARPHA Health Research Conference.

The Biodetection Technologies Conference, an internationally recognized meeting for experts in detection and identification of biological threats held on June 18, will focus on point-of-care diagnostics for improving global health and biodefence. Co-Diagnostics' presentation at 12:30 pm ET will include a discussion of its point-of-care and at-home rapid PCR diagnostics platform currently in development, as the platform relates to supporting sample-to-result COVID-19 testing initiatives at the places where interactions take place to help normalize work, school, home and travel routines. The presentation will also provide insight into aspects of the underlying CoPrimer™ technology and the results of the Company's analysis relative to global strains and variants of SARS-CoV-2.

The theme for the 2021 virtual Caribbean Public Health Agency (CARPHA) Health Research Conference, held June 16-19, 2021, is "Pandemic, NCDs and Climate Change: The Caribbean's Triple Threat." According to the conference website, NCDs, or non-communicable diseases, are the leading cause of death in the Caribbean region, which has also been greatly impacted by the effects of the COVID-19 pandemic. The Company has been attending the CARPHA conference since 2017, and its virtual booth will present Co-Diagnostics' infectious disease and vector control products to conference attendees.

To learn more about the two conferences, including registration details, please visit biodetectiontechnologies.com/point-of-care-diagnostics and carphaconference.vfairs.com. An archived version of the Biodetection Technologies presentation can be accessed on the Events and Webcasts section of the Co-Diagnostics website following the conclusion of the conference.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-upcoming-technology-and-health-research-conferences-301312630.html

SOURCE Co-Diagnostics

Co-Diagnostics Inc

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Salt Lake City

About CODX

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are